774
774
817
817
882
882
945
945
1402
1402
1618
1618
1875
1875
1762
1762
2036
2036
2393
2393
2019
2010
Hospital (28.2K)University (9.9K)Company (3.5K)Research Institution (3.3K)Foundation (570)Investor (376)Other (57)
1 - 10 of 28,254
Sort by
Publication
IDDOI:10.1200/jco.19.01381Published Date2020-02-20JournalJournal of Clinical Oncology, 2020-02-20, Volume 38
PURPOSE Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipilimumab at 3 mg/kg (ipi3) and ipi10 versus HDI. PATIENTS AND METHODS E1609 was a phase III trial in patients with resected cutaneous melanoma (American Joint Committee on Cancer 7th edition stage IIIB, IIIC, M1a, or M1b). It had 2 coprimary end poi…
Publication
ID31880964Published Date2020-02-20JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020-02-20, Volume 38
Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipilimumab at 3 mg/kg (ipi3) and ipi10 versus HDI.E1609 was a phase III trial in patients with resected cutaneous melanoma (American Joint Committee on Cancer 7th edition stage IIIB, IIIC, M1a, or M1b). It had 2 coprimary end points: OS and RFS. A 2-step hier…
Publication
ID32068903Published Date2020-02-18JournalThe Laryngoscope, 2020-02-18
To describe the clinical presentation, management, and complications associated with button battery impaction in the aerodigestive tract in children.Retrospective case series.This multi-institutional study, endorsed by the American Society of Pediatric Otolaryngology research consortium, is a retrospective medical record review, including all children at five tertiary-care institutions presenting with button batteries impacted in the aerodigestive tract between January 2002 and December 2014.…
Publication
ID32067049Published Date2020-02-18JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020-02-18
Seasonal influenza causes substantial morbidity and mortality in older adults. High-dose inactivated influenza vaccine (HD-IIV), with increased antigen content compared to standard-dose influenza vaccines (SD-IIV), is licensed for use in people aged ≥65 years. We sought to evaluate the effectiveness of HD-IIV and SD-IIV for prevention of influenza-associated hospitalizations.Hospitalized patients with acute respiratory illness were enrolled in an observational vaccine effectiveness study at e…
Publication
ID31896620Published Date2020-02-18JournalNeurology, 2020-02-18, Volume 94
To investigate the safety and efficacy of escalating doses of the semi-synthetic triterpenoid omaveloxolone in patients with mitochondrial myopathy.In cohorts of 8-13, 53 participants were randomized double-blind to 12 weeks of treatment with omaveloxolone 5, 10, 20, 40, 80, or 160 mg, or placebo. Outcome measures were change in peak cycling exercise workload (primary), in 6-minute walk test (6MWT) distance (secondary), and in submaximal exercise heart rate and plasma lactate (exploratory).No…
Publication
ID31943168Published Date2020-03-01JournalCancer, 2020-03-01, Volume 126
The selection of later-line treatment for older patients with AJCC (version 7) stage IV non-small cell lung cancer (NSCLC) remains controversial. Nanoparticle albumin-bound (nab)-paclitaxel is approved with carboplatin for the first-line treatment of patients with NSCLC and subgroup analysis of phase 3 data has suggested superior survival in older patients.The authors conducted a phase 2 study of nab-paclitaxel in 42 patients aged ≥70 years who had been treated previously with a platinum doub…
Clinical Trial
Clinical Trial IDNCT04084080Start Date2020-03-01Completion Date0030-03-30PhasePhase 3Study TypeInterventionalStatusRecruiting
The SCD-CARRE trial is a Phase 3, prospective, randomized, multicenter, controlled, parallel two-arm study aimed to determine if automated exchange blood transfusion and standard of care administered to high mortality risk adult SCD patients reduces the total number of episodes of clinical worsening of SCD requiring acute health care encounters (non-elective infusion center/ER/hospital visits) or resulting in death over 12 months as compared with standard of care.
Clinical Trial
Clinical Trial IDNCT04017390Start Date2020-03-01Completion Date2021-10-01PhasePhase 4Study TypeInterventionalStatusRecruiting
Participation will be for approximately 21 days (3 study visits,1 week apart with allowance for scheduling conflicts). A topical (or placebo) foam alone or with a splint will be used. Demographic and symptom information will be obtained. At each visit 3 questionnaires (BCT, CTS-6, and DASH) will be completed and an ultrasound of the wrist (median nerve) will be done to document any change in symptoms and/or in the size of the nerve. Random assignment will be to one of 4 groups: foam or placeb…
Publication
ID30840224Published Date2020-03-01JournalHead and neck pathology, 2020-03-01, Volume 14
Choristomas and hamartomas within the oral cavity are relatively uncommon lesions and may present with diverse clinical and histopathological appearances. In this report, we describe two infant patients with hamartoma with ectopic meningothelial elements involving tongue and maxillary alveolar ridge. To the best of our knowledge, these are the first two cases in which a meningothelial proliferation has been identified in the oral cavity. Hamartoma with ectopic meningothelial elements is a rar…
Publication
ID32058369Published Date2020-03-01JournalCritical care medicine, 2020-03-01, Volume 48
A companion article reports the trajectory of long-term mortality and significant health-related quality of life disability among children encountering septic shock. In this article, the investigators examine critical illness factors associated with these adverse outcomes.Prospective, cohort-outcome study, conducted 2013-2017.Twelve United States academic PICUs.Critically ill children, 1 month to 18 years, with community-acquired septic shock requiring vasoactive-inotropic support.Illness sev…
We found 28,254 documents that match your Search
Research Grants: 1,588
Publications: 23,829
Patents: 31
Clinical Trials: 1,594
Web Documents: 1,212

Wellspring Search is the world's most comprehensive collection of enriched content about emerging and licensable technology innovations.


Already a member? Sign in